此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

EXERT-BC Protein: Protein Supplementation to Improve Body Composition After Treatment for Breast Cancer

EXERT-BC Protein: Randomized Study of Protein Supplementation to Improve Body Composition Improvement During Hypertrophy Exercise After Treatment for Breast Cancer

In this study, the investigators hypothesize that a high dose of post-workout protein after each exercise session will have greater improvements in changes in body composition, including muscle mass and percent body fat versus a workout alone.

研究概览

研究类型

介入性

注册 (估计的)

40

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Clinical Trials Contact
  • 电话号码:412-330-6151
  • 邮箱:ctgov@ahn.org

学习地点

    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15212
        • 招聘中
        • AHN Allegheny General Hospital
        • 接触:
          • Clinical Trials Contact
          • 电话号码:4123306151
          • 邮箱:ctgov@ahn.org
      • Pittsburgh、Pennsylvania、美国、15212
        • 尚未招聘
        • AHN Allegheny General Hospital
        • 接触:
          • Clinical Trials Contact
          • 电话号码:412-330-6151
          • 邮箱:ctgov@ahn.org

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

20年 至 89年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  1. Age 20-89 years
  2. Women prescribed exercise as a SOC
  3. Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast
  4. Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.
  5. Women with > 3 months of resistance training experience under expert guidance by a CSCS
  6. Must be able to read and understand English and consent for themselves.

Exclusion Criteria:

  1. Any current treatment with cytotoxic chemotherapy for breast cancer
  2. Inability to safely engage in group sessions of resistance training as deemed by study PI
  3. Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training
  4. Beta blocker or GLP-1 inhibitor medications
  5. Pregnant women
  6. Males
  7. Lactose intolerance
  8. Cow's milk or whey protein allergy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:60 grams of protein

Participants will be randomized to a post-workout protein consisting of either no protein or 60 g of whey protein. The protein is 100% cold processed and micro-filtered, non-GMO grass-fed whey protein isolate, soy and gluten free, unflavored, and unsweetened. This will include Irish Dairy (AGN Roots, Ireland), which is whey protein isolate and soy lecithin, and Raw GrassFed Whey, which is whey protein concentrate. Utilizing both will allow individuals with any sensitivity to have increased options. The powder will be weighed by EOC staff in a private room prior to mixing with 12 oz of filtered water to ensure adequate dosage. The protein will be mixed via a protein shaker bottle made of stainless steel (Bolde Bottle).

60 grams of whey protein

实验性的:0 grams of protein

Participants will be randomized to a post-workout protein consisting of either no protein or 60 g of whey protein. The protein is 100% cold processed and micro-filtered, non-GMO grass-fed whey protein isolate, soy and gluten free, unflavored, and unsweetened. This will include Irish Dairy (AGN Roots, Ireland), which is whey protein isolate and soy lecithin, and Raw GrassFed Whey, which is whey protein concentrate. Utilizing both will allow individuals with any sensitivity to have increased options. The powder will be weighed by EOC staff in a private room prior to mixing with 12 oz of filtered water to ensure adequate dosage. The protein will be mixed via a protein shaker bottle made of stainless steel (Bolde Bottle).

0 grams of whey protein

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Determine changes in pounds of muscle and fat mass after each exercise regimen
大体时间:Baseline and at program completion (within 4 weeks of exercise completion)
Baseline and at program completion (within 4 weeks of exercise completion)

次要结果测量

结果测量
措施说明
大体时间
Determine changes in resting metabolic rate in calories per day at the completion of the exercise regimen
大体时间:Baseline and at program completion (within 4 weeks of exercise completion)
Baseline and at program completion (within 4 weeks of exercise completion)
Determine changes in body composition at the completion of the exercise regimen, including body mass in pounds, fat mass in pounds, fat-free mass in pounds, % fat, and % fat-free mass
大体时间:Baseline and at program completion (within 4 weeks of exercise completion)
Baseline and at program completion (within 4 weeks of exercise completion)
Determine changes in Y-balance score at the completion of the exercise regimen
大体时间:Baseline and at program completion (within 4 weeks of exercise completion)

Y-Balance score measures the length an individual can extend their foot. The larger the score the better the balance.

Baseline and at program completion (within 4 weeks of exercise completion)
Functional Movement Screen (FMS) scores at the completion of the exercise regimen
大体时间:Baseline and at program completion (within 4 weeks of exercise completion)

FMS measures movement patterns with scoring from 0 to 21. The large the score the better the mobility.

Baseline and at program completion (within 4 weeks of exercise completion)
Determine changes in phase angle at the completion of the exercise regimen
大体时间:At program completion (at 8 weeks)

Phase angle measures the fluidity of cells and the larger the value the better.

At program completion (at 8 weeks)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Colin Champ, MD, CSCS、AHN Radiation Oncology

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月18日

初级完成 (估计的)

2027年6月1日

研究完成 (估计的)

2028年6月1日

研究注册日期

首次提交

2026年7月7日

首先提交符合 QC 标准的

2026年7月14日

首次发布 (实际的)

2026年7月15日

研究记录更新

最后更新发布 (实际的)

2026年9月28日

上次提交的符合 QC 标准的更新

2026年9月25日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅